Bioversys N Logo

Bioversys N

BIOV | SW

Overview

Corporate Details

ISIN(s):
CH0210362643 (+1 more)
LEI:
894500UFIGC75NPZEZ68
Country:
Switzerland
Address:
Hochbergerstrasse 60C, 4057 Basel
Sector:
Health Care
Industry:
Biotechnology

Description

Bioversys N, based in Switzerland, is a biotechnology company focused on developing innovative solutions to combat antibiotic resistance.

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-03 07:00
General Meeting Notice
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
English 11.6 KB
2025-06-03 02:00
General Meeting Notice
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
English 11.0 KB
2025-04-30 00:00
Investor Presentation
BioVersys Corporate Presentation
English 3.2 MB
2025-04-28 07:00
Regulatory News Service
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
English 8.5 KB
2025-04-28 02:00
Inside Information Statement
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
English 7.2 KB
2025-04-08 07:00
Regulatory News Service
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
English 29.7 KB
2025-03-31 07:00
Regulatory News Service
BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE
English 11.6 KB
2025-03-27 07:00
Regulatory News Service
BIOVERSYS REPORTS CORPORATE HIGHLIGHTS AND KEY FINANCIALS FOR THE FULL YEAR 2024
English 25.6 KB
2025-03-27 00:00
Regulatory News Service
Webcast Financial Results 2024 & Business update
English 301.8 KB
2025-03-26 07:00
Regulatory News Service
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
English 30.4 KB
2025-03-26 01:00
Regulatory News Service
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
English 27.1 KB
2025-03-26 00:00
Regulatory News Service
BioVersys Annual Report 2024
English 6.9 MB
2025-03-20 07:00
Regulatory News Service
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-…
English 21.0 KB
2025-03-19 07:00
Regulatory News Service
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-…
English 21.0 KB
2025-03-14 07:00
Earnings Release
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVE…
English 6.1 KB

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PREDILIFE Logo PREDILIFE France ALPRE
PROSPEX ENERGY PLC Logo PROSPEX ENERGY PLC United Kingdom PXEN
Prostatype Genomics AB Logo Prostatype Genomics AB Sweden PROGEN
Psych Capital Plc Logo Psych Capital Plc United Kingdom PSY
Pure Biologics S.A. Logo Pure Biologics S.A. Poland PUR
Puretech Health PLC Logo Puretech Health PLC United States of America PRTC
Purple Biotech Ltd. Logo Purple Biotech Ltd. Israel PPBT
QLife Holding AB Logo QLife Holding AB Sweden QLIFE
Quantum Genomics Logo Quantum Genomics France ALQGC
QUIA PHARMA AB Logo QUIA PHARMA AB Sweden QUIA